Drugs / TS-ONE
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02024841 | Dec 2013 → Feb 2017 | gastric cancer, peritoneal carcinomatosis | The University of Hong Kong | Completed | No outcome recorded |
| Phase 1 | NCT01096199 | ? → Sep 2012 | cancer | National University Hospital, Singapore | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01228045 | Feb 2011 → Dec 2014 | gastric cancer | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 2 | NCT01736410 | May 2010 → Apr 2013 | carcinoma | National Cancer Centre, Singapore | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TS-ONE | “Intraperitoneal docetaxel, intravenous cisplatin and oral TS-ONE every 3 weeks for 3 cycles then stop” NCT02024841 ↗3“TS-ONE is orally administered consecutive 14-day followed by 7-day rest.” NCT01736410 ↗ |
| Route | Oral | “TS-ONE is orally administered consecutive 14-day followed by 7-day rest.” NCT01228045 ↗ |